<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32779318</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2184</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>53</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell proliferation</Title>
          <ISOAbbreviation>Cell Prolif</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression.</ArticleTitle>
        <Pagination>
          <StartPage>e12887</StartPage>
          <MedlinePgn>e12887</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e12887</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cpr.12887</ELocationID>
        <Abstract>
          <AbstractText>LncRNAs play a pivotal role in the regulation of epigenetic modification, cell cycle, differentiation, proliferation, migration and other physiological activities. In particular, considerable studies have shown that the aberrant expression and dysregulation of lncRNAs are widely implicated in cancer initiation and progression by acting as tumour promoters or suppressors. Hippo signalling pathway has attracted researchers' attention as one of the critical cancer-related pathways in recent years. Increasing evidences have demonstrated that lncRNAs could interact with Hippo cascade and thereby contribute to acquisition of multiple malignant hallmarks, including proliferation, metastasis, relapse and resistance to anti-cancer treatment. Specifically, Hippo signalling pathway is reported to modulate or be regulated by widespread lncRNAs. Intriguingly, certain lncRNAs could form a reciprocal feedback loop with Hippo signalling. More speculatively, lncRNAs related to Hippo pathway have been poised to become important putative biomarkers and therapeutic targets in human cancers. Herein, this review focuses on the crosstalk between lncRNAs and Hippo pathway in carcinogenesis, summarizes the comprehensive role of Hippo-related lncRNAs in tumour progression and depicts their clinical diagnostic, prognostic or therapeutic potentials in tumours.</AbstractText>
          <CopyrightInformation>© 2020 The Authors. Cell Proliferation published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tu</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Kexin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Jieyu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wanchun</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Qiong</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0002-0126-4978</Identifier>
            <AffiliationInfo>
              <Affiliation>Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zhihong</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-1944-9671</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Prolif</MedlineTA>
        <NlmUniqueID>9105195</NlmUniqueID>
        <ISSNLinking>0960-7722</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090683" MajorTopicYN="N">Hippo Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Hippo</Keyword>
        <Keyword MajorTopicYN="N">LncRNA</Keyword>
        <Keyword MajorTopicYN="N">YAP</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">crosstalk</Keyword>
        <Keyword MajorTopicYN="N">sarcoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32779318</ArticleId>
        <ArticleId IdType="pmc">PMC7507458</ArticleId>
        <ArticleId IdType="doi">10.1111/cpr.12887</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Tu C, Ren X, He J, et al. The predictive value of lncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors. Cancer Cell Int. 2020;20:115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7137300</ArticleId>
            <ArticleId IdType="pubmed">32280307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saad El Din K, Loree JM, Sayre EC, et al. Trends in the epidemiology of young‐onset colorectal cancer: a worldwide systematic review. BMC Cancer. 2020;20:288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7137305</ArticleId>
            <ArticleId IdType="pubmed">32252672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363‐385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31184787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tu C, Ren X, He J, et al. The value of LncRNA BCAR4 as a prognostic biomarker on clinical outcomes in human cancers. J Cancer. 2019;10:5992‐6002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6856575</ArticleId>
            <ArticleId IdType="pubmed">31762809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang C, Ren X, He J, Wang W, Tu C, Li Z. The prognostic value of long noncoding RNA SNHG16 on clinical outcomes in human cancers: a systematic review and meta‐analysis. Cancer Cell Int. 2019;19:261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6788067</ArticleId>
            <ArticleId IdType="pubmed">31632195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bin X, Hongjian Y, Xiping Z, Bo C, Shifeng Y, Binbin T. Research progresses in roles of LncRNA and its relationships with breast cancer. Cancer Cell Int. 2018;18:179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6233376</ArticleId>
            <ArticleId IdType="pubmed">30459529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ren X, He J, Qi L, et al. Prognostic and clinicopathologic significance of long non‐coding RNA opa‐interacting protein 5‐antisense RNA 1 in multiple human cancers. Artif Cells Nanomed Biotechnol. 2020;48:353‐361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31899963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xiao M, Feng Y, Liu C, Zhang Z. Prognostic values of long noncoding RNA PVT1 in various carcinomas: an updated systematic review and meta‐analysis. Cell Prolif. 2018;51:e12519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6528925</ArticleId>
            <ArticleId IdType="pubmed">30252166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yao F, Wang Q, Wu Q. The prognostic value and mechanisms of lncRNA UCA1 in human cancer. Cancer Manag Res. 2019;11:7685‐7696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6698587</ArticleId>
            <ArticleId IdType="pubmed">31616184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brannan CI, Dees EC, Ingram RS, Tilghman SM. The product of the H19 gene may function as an RNA. Mol Cell Biol. 1990;10:28‐36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC360709</ArticleId>
            <ArticleId IdType="pubmed">1688465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ni W, Yao S, Zhou Y, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m(6)A reader YTHDF3. Mol Cancer. 2019;18:143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6794841</ArticleId>
            <ArticleId IdType="pubmed">31619268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang C, Qian H, Liu K, Zhao W, Wang L. A feedback loop regulation of LINC01433 and YAP promotes malignant behavior in gastric cancer cells. Onco Targets Ther. 2019;12:7949‐7962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6778481</ArticleId>
            <ArticleId IdType="pubmed">31632054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tu C, He J, Chen R, Li Z. The emerging role of exosomal non‐coding RNAs in musculoskeletal diseases. Curr Pharm Des. 2019;25:4523‐4535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31724510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
He J, Tu C, Liu Y. Role of lncRNAs in aging and age‐related diseases. Aging Med (Milton). 2018;1:158‐175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6880696</ArticleId>
            <ArticleId IdType="pubmed">31942494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chi Y, Wang D, Wang J, Yu W, Yang J. Long non‐coding RNA in the pathogenesis of cancers. Cells. 2019;8:1015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6770362</ArticleId>
            <ArticleId IdType="pubmed">31480503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Qu J, Kamal MA, Yuan C. The regulatory roles of long non‐coding RNA in the chemoresistance process of ovarian cancer. Curr Pharm Des. 2019;25:856‐861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30947657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9:1354‐1366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6682721</ArticleId>
            <ArticleId IdType="pubmed">31392074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fattahi S, Kosari‐Monfared M, Golpour M, et al. LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: a novel approach to personalized medicine. J Cell Physiol. 2020;235:3189‐3206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31595495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thompson BJ. YAP/TAZ: drivers of tumor growth, metastasis, and resistance to therapy. BioEssays. 2020;42:e1900162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32128850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang LX, Wu J, Guo ML, Zhang Y, Ma SG. Suppression of long non‐coding RNA TNRC6C‐AS1 protects against thyroid carcinoma through DNA demethylation of STK4 via the Hippo signalling pathway. Cell Prolif. 2019;52:e12564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6536409</ArticleId>
            <ArticleId IdType="pubmed">30938030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995;9:534‐546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7698644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zygulska AL, Krzemieniecki K, Pierzchalski P. Hippo pathway ‐ brief overview of its relevance in cancer. J Physiol Pharmacol. 2017;68:311‐335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28820389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell. 2008;13:188‐192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18328423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747‐2761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Snigdha K, Gangwani KS, Lapalikar GV, Singh A, Kango‐Singh M. Hippo signaling in cancer: lessons from drosophila models. Front Cell Dev Biol. 2019;7:85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6558396</ArticleId>
            <ArticleId IdType="pubmed">31231648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zheng X, Han H, Liu GP, et al. LncRNA wires up Hippo and Hedgehog signaling to reprogramme glucose metabolism. EMBO J. 2017;36:3325‐3335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5686550</ArticleId>
            <ArticleId IdType="pubmed">28963395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fu PF, Zheng X, Fan X, Lin AF. Role of cytoplasmic lncRNAs in regulating cancer signaling pathways. J Zhejiang Univ Sci B. 2019;20:1‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6331333</ArticleId>
            <ArticleId IdType="pubmed">30614225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811‐828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4638384</ArticleId>
            <ArticleId IdType="pubmed">26544935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kovar H, Bierbaumer L, Radic‐Sarikas B. The YAP/TAZ pathway in osteogenesis and bone sarcoma pathogenesis. Cells. 2020;9:972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7227004</ArticleId>
            <ArticleId IdType="pubmed">32326412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pobbati AV, Hong W. A combat with the YAP/TAZ‐TEAD oncoproteins for cancer therapy. Theranostics. 2020;10:3622‐3635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7069086</ArticleId>
            <ArticleId IdType="pubmed">32206112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shimoda M, Moroishi T. The emerging link between the hippo pathway and non‐coding RNA. Biol Pharm Bull. 2020;43:1‐10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31902912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shen Y, Gao X, Tan W, Xu T. STAT1‐mediated upregulation of lncRNA LINC00174 functions a ceRNA for miR‐1910‐3p to facilitate colorectal carcinoma progression through regulation of TAZ. Gene. 2018;666:64‐71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29729381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zheng Y, Pan D. The Hippo signaling pathway in development and disease. Dev Cell. 2019;50:264‐282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6748048</ArticleId>
            <ArticleId IdType="pubmed">31386861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao B, Lei QY, Guan KL. The Hippo‐YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol. 2008;20:638‐646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3296452</ArticleId>
            <ArticleId IdType="pubmed">18955139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang Y, Fang Z, Guo X, et al. lncRNA B4GALT1‐AS1 promotes colon cancer cell stemness and migration by recruiting YAP to the nucleus and enhancing YAP transcriptional activity. J Cell Physiol. 2019;234:18524‐18534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30912138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guan ZB, Cao YS, Li Y, Tong WN, Zhuo AS. Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Cancer Biomark. 2018;21:557‐563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29286919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang C, Wu K, Wang S, Wei G. Long non‐coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR‐195‐5p. J Cell Biochem. 2018;119:5646‐5656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29384226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li Z, Wang Y, Hu R, Xu R, Xu W. LncRNA B4GALT1‐AS1 recruits HuR to promote osteosarcoma cells stemness and migration via enhancing YAP transcriptional activity. Cell Prolif. 2018;51:e12504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6528912</ArticleId>
            <ArticleId IdType="pubmed">30182452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang D, Zhang H, Fang X, Zhang X, Liu H. Prognostic value of long non‐coding RNA GHET1 in cancers: a systematic review and meta‐analysis. Cancer Cell Int. 2020;20:109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7137500</ArticleId>
            <ArticleId IdType="pubmed">32280301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu W, Xiang D, Jia H, et al. The lncRNA BCYRN1 functions as an oncogene in human glioma by downregulating miR‐125a‐5p in vitro. Cancer Manag Res. 2020;12:1151‐1161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7025664</ArticleId>
            <ArticleId IdType="pubmed">32104095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang Y, Xue C, Zhu X, Zhu X, Xian H, Huang Z. Suppression of microRNA‐125a‐5p upregulates the TAZ‐EGFR signaling pathway and promotes retinoblastoma proliferation. Cell Signal. 2016;28:850‐860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27094723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su X, Teng J, Jin G, et al. ELK1‐induced upregulation of long non‐coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2. Biomed Pharmacother. 2019;109:788‐797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30551532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang S, Ke H, Zhang H, et al. LncRNA MIR100HG promotes cell proliferation in triple‐negative breast cancer through triplex formation with p27 loci. Cell Death Dis. 2018;9:805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6057987</ArticleId>
            <ArticleId IdType="pubmed">30042378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Emmrich S, Streltsov A, Schmidt F, Thangapandi VR, Reinhardt D, Klusmann JH. LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. Mol Cancer. 2014;13:171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4118279</ArticleId>
            <ArticleId IdType="pubmed">25027842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yeung B, Yu J, Yang X. Roles of the Hippo pathway in lung development and tumorigenesis. Int J Cancer. 2016;138:533‐539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25644176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu Y, He D, Bo H, et al. The MRVI1‐AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo‐TAZ pathway. Oncogene. 2019;38:6065‐6081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31273338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu W, Qiao Y, Tang X, et al. Tumor suppressor long non‐coding RNA, MT1DP is negatively regulated by YAP and Runx2 to inhibit FoxA1 in liver cancer cells. Cell Signal. 2014;26:2961‐2968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25261601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huang L, Mo Z, Hu Z, et al. Diagnostic value of fibrinogen to prealbumin ratio and gamma‐glutamyl transpeptidase to platelet ratio in the progression of AFP‐negative hepatocellular carcinoma. Cancer Cell Int. 2020;20:77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7066792</ArticleId>
            <ArticleId IdType="pubmed">32190001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fan J, He S, Zheng Y. Analyses of clinical efficacy of ultrasound‐guided radiofrequency ablation in liver cancer adjacent to the gallbladder and its prognosis. J BUON. 2019;24:2411‐2417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31983113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Y, Li M, Yu H, Piao H. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR125a5p. Int J Mol Med. 2020;45:497‐509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6984795</ArticleId>
            <ArticleId IdType="pubmed">31894257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ou C, Sun Z, He X, et al. Targeting YAP1/LINC00152/FSCN1 signaling axis prevents the progression of colorectal cancer. Adv Sci (Weinh). 2020;7:1901380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7001651</ArticleId>
            <ArticleId IdType="pubmed">32042551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tan BS, Yang MC, Singh S, et al. LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene. 2019;38:5612‐5626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30967631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene. 2014;33:4857‐4866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24141783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang J, Yin M, Huang J, et al. Long noncoding RNA LINC00152 as a novel predictor of lymph node metastasis and survival in human cancer: a systematic review and meta‐analysis. Clin Chim Acta. 2018;483:25‐32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29617624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ventura A. NORAD: defender of the genome. Trends Genet. 2016;32:390‐392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27157388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang Z, Zhao Y, Lin G, Zhou X, Jiang X, Zhao H. Noncoding RNA activated by DNA damage (NORAD): biologic function and mechanisms in human cancers. Clin Chim Acta. 2019;489:5‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30468715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou K, Ou Q, Wang G, Zhang W, Hao Y, Li W. High long non‐coding RNA NORAD expression predicts poor prognosis and promotes breast cancer progression by regulating TGF‐beta pathway. Cancer Cell Int. 2019;19:63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6425604</ArticleId>
            <ArticleId IdType="pubmed">30930692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
An LF, Huang JW, Han X, Wang J. Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR‐18b/IGF1 axis. Anticancer Drugs. 2020;31:473‐482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32265386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang X, Pei X, Guo G, et al. Exosome‐mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer. J Cell Physiol. 2020. 
10.1002/jcp.29585
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.29585</ArticleId>
            <ArticleId IdType="pubmed">31994191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang Y, Zhu R, Wang J, Cui Z, Wang Y, Zhao Y. Upregulation of lncRNA H19 promotes nasopharyngeal carcinoma proliferation and metastasis in let‐7 dependent manner. Artif Cells Nanomed Biotechnol. 2019;47:3854‐3861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31556327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li D, Hao S, Zhang J. Long non‐coding RNA UCA1 exerts growth modulation by miR‐15a in human thyroid cancer TPC‐1 cells. Artif Cells Nanomed Biotechnol. 2019;47:1815‐1822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31062608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin X, Spindler TJ, de Souza Fonseca MA, et al. Super‐enhancer‐associated LncRNA UCA1 interacts directly with AMOT to activate YAP target genes in epithelial ovarian cancer. iScience.. 2019;17:242‐255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6629722</ArticleId>
            <ArticleId IdType="pubmed">31307004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mota MSV, Jackson WP, Bailey SK, et al. Deficiency of tumor suppressor Merlin facilitates metabolic adaptation by co‐operative engagement of SMAD‐Hippo signaling in breast cancer. Carcinogenesis. 2018;39:1165‐1175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6148973</ArticleId>
            <ArticleId IdType="pubmed">29893810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang M, Zhao Y, Zhang Y, et al. LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1770‐1782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29510195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gao ZQ, Wang JF, Chen DH, et al. Long non‐coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down‐regulation of miR‐181c‐5p. Biomed Pharmacother. 2018;97:809‐817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29112934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun Y, Jiang T, Jia Y, Zou J, Wang X, Gu W. LncRNA MALAT1/miR‐181a‐5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo‐YAP signaling pathway. Cell Cycle. 2019;18:2509‐2523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6738907</ArticleId>
            <ArticleId IdType="pubmed">31397203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang J, Wang H, Zhang Y, et al. Mutual inhibition between YAP and SRSF1 maintains long non‐coding RNA, Malat1‐induced tumourigenesis in liver cancer. Cell Signal. 2014;26:1048‐1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24468535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou Y, Shan T, Ding W, et al. Study on mechanism about long noncoding RNA MALAT1 affecting pancreatic cancer by regulating Hippo‐YAP signaling. J Cell Physiol. 2018;233:5805‐5814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29215734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu W, Yan Z, Hu F, Wei W, Yang C, Sun Z. Long non‐coding RNA GAS5 accelerates oxidative stress in melanoma cells by rescuing EZH2‐mediated CDKN1C downregulation. Cancer Cell Int. 2020;20:116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7146881</ArticleId>
            <ArticleId IdType="pubmed">32308561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gao C, Ren C, Liu Z, Zhang L, Tang R, Li X. GAS5, a FoxO1‐actived long noncoding RNA, promotes propofol‐induced oral squamous cell carcinoma apoptosis by regulating the miR‐1297‐GSK3beta axis. Artif Cells Nanomed Biotechnol. 2019;47:3985‐3993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31583913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6‐methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6892141</ArticleId>
            <ArticleId IdType="pubmed">31801551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jin D, Guo J, Wu Y, et al. m(6)A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs‐mediated YAP expression and inhibiting miR‐107/LATS2‐mediated YAP activity in NSCLC. Mol Cancer. 2020;19:40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7045432</ArticleId>
            <ArticleId IdType="pubmed">32106857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jin D, Guo J, Wu Y, et al. m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1‐miR‐1914‐3p‐YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12:135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6902496</ArticleId>
            <ArticleId IdType="pubmed">31818312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su Y, Wu H, Pavlosky A, et al. Regulatory non‐coding RNA: new instruments in the orchestration of cell death. Cell Death Dis. 2016;7:e2333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5108314</ArticleId>
            <ArticleId IdType="pubmed">27512954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wen J, Chen L, Tian H, et al. Effect of MALAT1 polymorphisms on papillary thyroid cancer in a chinese population. J Cancer. 2019;10:5714‐5721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6879318</ArticleId>
            <ArticleId IdType="pubmed">31788131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu S, Qiu J, He G, et al. LncRNA MALAT1 acts as a miR‐125a‐3p sponge to regulate FOXM1 expression and promote hepatocellular carcinoma progression. J Cancer. 2019;10:6649‐6659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6856878</ArticleId>
            <ArticleId IdType="pubmed">31777593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tan M, Jiang B, Wang H, et al. Dihydromyricetin induced lncRNA MALAT1‐TFEB‐dependent autophagic cell death in cutaneous squamous cell carcinoma. J Cancer. 2019;10:4245‐4255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6691703</ArticleId>
            <ArticleId IdType="pubmed">31413743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Qi F, Tan B, Ma F, et al. A Synthetic Light‐switchable System based on CRISPR Cas13a regulates the expression of LncRNA MALAT1 and affects the malignant phenotype of bladder cancer cells. Int J Biol Sci. 2019;15:1630‐1636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6643210</ArticleId>
            <ArticleId IdType="pubmed">31360106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li H, He C, Wang X, Wang H, Nan G, Fang L. MicroRNA‐183 affects the development of gastric cancer by regulating autophagy via MALAT1‐miR‐183‐SIRT1 axis and PI3K/AKT/mTOR signals. Artif Cells Nanomed Biotechnol. 2019;47:3163‐3171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31352788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965‐3981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28701486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim J, Piao HL, Kim BJ, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50:1705‐1715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6265076</ArticleId>
            <ArticleId IdType="pubmed">30349115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gomes CP, Nobrega‐Pereira S, Domingues‐Silva B, et al. An antisense transcript mediates MALAT1 response in human breast cancer. BMC Cancer. 2019;19:771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6683341</ArticleId>
            <ArticleId IdType="pubmed">31382922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen Q, Zhu C, Jin Y. The oncogenic and tumor suppressive functions of the long noncoding RNA MALAT1: an emerging controversy. Front Genet. 2020;11:93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7056701</ArticleId>
            <ArticleId IdType="pubmed">32174966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gao L, Cao H, Cheng X. A positive feedback regulation between long noncoding RNA SNHG1 and YAP1 modulates growth and metastasis in laryngeal squamous cell carcinoma. Am J Cancer Res. 2018;8:1712‐1724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6176179</ArticleId>
            <ArticleId IdType="pubmed">30323965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li N, Yang G, Luo L, et al. lncRNA THAP9‐AS1 promotes pancreatic ductal adenocarcinoma growth and leads to a poor clinical outcome via sponging miR‐484 and interacting with YAP. Clin Cancer Res. 2020;26:1736‐1748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31831555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dong B, Chen X, Zhang Y, Zhu C, Dong Q. The prognostic value of lncRNA SNHG1 in cancer patients: a meta‐analysis. BMC Cancer. 2019;19:780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6686246</ArticleId>
            <ArticleId IdType="pubmed">31391030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiang Z, Jiang C, Fang J. Up‐regulated lnc‐SNHG1 contributes to osteosarcoma progression through sequestration of miR‐577 and activation of WNT2B/Wnt/beta‐catenin pathway. Biochem Biophys Res Commun. 2018;495:238‐245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29108989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cui L, Dong Y, Wang X, et al. Downregulation of long noncoding RNA SNHG1 inhibits cell proliferation, metastasis, and invasion by suppressing the Notch‐1 signaling pathway in pancreatic cancer. J Cell Biochem. 2019;120:6106‐6112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30520072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125:1253‐1267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3026384</ArticleId>
            <ArticleId IdType="pubmed">16814713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li S, Yu Z, Chen SS, et al. The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. Urol Oncol. 2015;33(10):427. e421‐410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26163939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cui X, Piao C, Lv C, Lin X, Zhang Z, Liu X. ZNFX1 anti‐sense RNA 1 promotes the tumorigenesis of prostate cancer by regulating c‐Myc expression via a regulatory network of competing endogenous RNAs. Cell Mol Life Sci. 2020;77:1135‐1152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31321444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun Z, Ou C, Liu J, et al. YAP1‐induced MALAT1 promotes epithelial‐mesenchymal transition and angiogenesis by sponging miR‐126‐5p in colorectal cancer. Oncogene. 2019;38:2627‐2644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6484768</ArticleId>
            <ArticleId IdType="pubmed">30531836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matsuda Y, Narita S, Nara T, et al. Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high‐risk localized prostate cancer. BMC Cancer. 2020;20:302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7333261</ArticleId>
            <ArticleId IdType="pubmed">32293349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bouvier C, Macagno N, Nguyen Q, et al. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and beta1‐integrin in conventional osteosarcoma. Oncotarget. 2016;7:64702‐64710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5323109</ArticleId>
            <ArticleId IdType="pubmed">27608849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang CZ, Yan GX, Dong DS, Xin H, Liu ZY. LncRNA‐ATB promotes autophagy by activating Yes‐associated protein and inducing autophagy‐related protein 5 expression in hepatocellular carcinoma. World J Gastroenterol. 2019;25:5310‐5322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6761242</ArticleId>
            <ArticleId IdType="pubmed">31558875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ni W, Zhang Y, Zhan Z, et al. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A‐mediated ubiquitination of LATS1. J Hematol Oncol. 2017;10:91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5395742</ArticleId>
            <ArticleId IdType="pubmed">28420424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lv GY, Miao J, Zhang XL. Long noncoding RNA XIST promotes osteosarcoma progression by targeting RAS‐related protein RAP2B via miR‐320b. Oncol Res. 2018;26:837‐846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7844768</ArticleId>
            <ArticleId IdType="pubmed">28409547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun X, Wei B, Peng ZH, et al. Knockdown of lncRNA XIST suppresses osteosarcoma progression by inactivating AKT/mTOR signaling pathway by sponging miR‐375‐3p. Int J Clin Exp Pathol. 2019;12:1507‐1517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6947095</ArticleId>
            <ArticleId IdType="pubmed">31933968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang W, Shen H, Cao G, Huang J. Long non‐coding RNA XIST predicts poor prognosis and promotes malignant phenotypes in osteosarcoma. Oncol Lett. 2019;17:256‐262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6313160</ArticleId>
            <ArticleId IdType="pubmed">30655762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li GL, Wu YX, Li YM, Li J. High expression of long non‐coding RNA XIST in osteosarcoma is associated with cell proliferation and poor prognosis. Eur Rev Med Pharmacol Sci. 2017;21:2829‐2834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28682435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu T, Jiang W, Fan L, Gao Q, Li G. Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21. Oncotarget. 2017;8:101406‐101417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5731884</ArticleId>
            <ArticleId IdType="pubmed">29254174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deng C, Hu X, Wu K, Tan J, Yang C. Long non‐coding RNA XIST predicting advanced clinical parameters in cancer: A Meta‐Analysis and case series study in a single institution. Oncol Lett. 2019;18:2192‐2202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6676735</ArticleId>
            <ArticleId IdType="pubmed">31404342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu DM, Wang S, Wen X, et al. LncRNA SNHG15 acts as a ceRNA to regulate YAP1‐Hippo signaling pathway by sponging miR‐200a‐3p in papillary thyroid carcinoma. Cell Death Dis. 2018;9:947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6148237</ArticleId>
            <ArticleId IdType="pubmed">30237435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su L, Wang S, Yuan T, et al. Anti‐oral squamous cell carcinoma effects of a potent TAZ inhibitor AR‐42. J Cancer. 2020;11:364‐373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6930442</ArticleId>
            <ArticleId IdType="pubmed">31897232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang Z, Qiu N, Yin J, et al. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression. Theranostics. 2020;10:4290‐4307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7150493</ArticleId>
            <ArticleId IdType="pubmed">32292495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mao B, Hu F, Cheng J, et al. SIRT1 regulates YAP2‐mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 2014;33:1468‐1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23542177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang DY, Wu YN, Huang JQ, et al. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chin J Cancer. 2016;35:47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4875723</ArticleId>
            <ArticleId IdType="pubmed">27206784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cournoyer S, Addioui A, Belounis A, et al. GX15‐070 (Obatoclax), a Bcl‐2 family proteins inhibitor engenders apoptosis and pro‐survival autophagy and increases Chemosensitivity in neuroblastoma. BMC Cancer. 2019;19:1018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6819521</ArticleId>
            <ArticleId IdType="pubmed">31664947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang X, Lan Z, He J, et al. LncRNA SNHG6 promotes chemoresistance through ULK1‐induced autophagy by sponging miR‐26a‐5p in colorectal cancer cells. Cancer Cell Int. 2019;19:234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6734319</ArticleId>
            <ArticleId IdType="pubmed">31516391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wilkinson DS, Hansen M. LC3 is a novel substrate for the mammalian Hippo kinases, STK3/STK4. Autophagy. 2015;11:856‐857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509446</ArticleId>
            <ArticleId IdType="pubmed">25996575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jin KT, Lu ZB, Lv JQ, Zhang JG. The role of long non‐coding RNAs in mediating chemoresistance by modulating autophagy in cancer. RNA Biol. 2020;1‐14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7714480</ArticleId>
            <ArticleId IdType="pubmed">32129701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shen S, Huang K, Wu Y, et al. A miR‐135b‐TAZ positive feedback loop promotes epithelial‐mesenchymal transition (EMT) and tumorigenesis in osteosarcoma. Cancer Lett. 2017;407:32‐44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28823959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li CH, Chen Y. Targeting long non‐coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013;45:1895‐1910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23748105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
d'Ydewalle C, Ramos DM, Pyles NJ, et al. The antisense transcript SMN‐AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron. 2017;93:66‐79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5223741</ArticleId>
            <ArticleId IdType="pubmed">28017471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Amodio N, Stamato MA, Juli G, et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti‐multiple myeloma activity. Leukemia. 2018;32:1948‐1957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6127082</ArticleId>
            <ArticleId IdType="pubmed">29487387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jin SJ, Jin MZ, Xia BR, Jin WL. Long non‐coding RNA DANCR as an emerging therapeutic target in human cancers. Front Oncol. 2019;9:1225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6874123</ArticleId>
            <ArticleId IdType="pubmed">31799189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu H, Luo J, Luan S, He C, Li Z. Long non‐coding RNAs involved in cancer metabolic reprogramming. Cell Mol Life Sci. 2019;76:495‐504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30341461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jia Y, Jin H, Gao L, et al. A novel lncRNA PLK4 up‐regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP‐mediated cell senescence. J Cell Mol Med. 2020;24(9):5304‐5316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7205816</ArticleId>
            <ArticleId IdType="pubmed">32243714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baldwin P, Ohman AW, Medina JE, McCarthy ET, Dinulescu DM, Sridhar S. Nanoformulation of talazoparib delays tumor progression and ascites formation in a late stage cancer model. Front Oncol. 2019;9:353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6524318</ArticleId>
            <ArticleId IdType="pubmed">31134152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Exman P, Barroso‐Sousa R, Tolaney SM. Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther. 2019;12:5177‐5187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6612288</ArticleId>
            <ArticleId IdType="pubmed">31303769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stepan J, Anderzhanova E, Gassen NC. Hippo signaling: emerging pathway in stress‐related psychiatric disorders?
Front Psychiatry. 2018;9:715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6309125</ArticleId>
            <ArticleId IdType="pubmed">30627107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen S, Wang LL, Sun KX, et al. LncRNA PCGEM1 induces ovarian carcinoma tumorigenesis and progression through RhoA pathway. Cell Physiol Biochem. 2018;47:1578‐1588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29949791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Du X, Yu A, Tao W. The non‐canonical Hippo/Mst pathway in lymphocyte development and functions. Acta Biochim Biophys Sin (Shanghai). 2015;47:60‐64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25487919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
An L, Nie P, Chen M, et al. MST4 kinase suppresses gastric tumorigenesis by limiting YAP activation via a non‐canonical pathway. J Exp Med. 2020;217:e20191817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32271880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aboudehen K. Regulation of mTOR signaling by long non‐coding RNA. Biochim Biophys Acta Gene Regul Mech. 2020;1863:194449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7125019</ArticleId>
            <ArticleId IdType="pubmed">31751821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su R, Ma J, Zheng J, et al. PABPC1‐induced stabilization of BDNF‐AS inhibits malignant progression of glioblastoma cells through STAU1‐mediated decay. Cell Death Dis. 2020;11:81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6997171</ArticleId>
            <ArticleId IdType="pubmed">32015336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang J, Li Z, Wang X, Ding Y, Li N. The tumor suppressive effect of long non‐coding RNA FRMD6‐AS2 in uteri corpus endometrial carcinoma. Life Sci. 2020;243:117254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31917993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li C, Wang S, Xing Z, et al. A ROR1‐HER3‐lncRNA signalling axis modulates the Hippo‐YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017;19:106‐119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5336186</ArticleId>
            <ArticleId IdType="pubmed">28114269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang C, Bao C, Zhang X, Lin X, Pan D, Chen Y. Knockdown of lncRNA LEF1‐AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway. Cancer Biol Ther. 2019;20:1213‐1222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6741770</ArticleId>
            <ArticleId IdType="pubmed">30983488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Z, Yao Y, Huang S, et al. LINC00662 promotes gastric cancer cell growth by modulating the Hippo‐YAP1 pathway. Biochem Biophys Res Commun. 2018;505:843‐849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30297104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Qiao K, Ning S, Wan L, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR‐515‐5p/MARK4/Hippo signaling pathway. J Exp Clin Cancer Res. 2019;38:418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6796384</ArticleId>
            <ArticleId IdType="pubmed">31623640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen L, Chen Q, Kuang S, et al. USF1‐induced upregulation of LINC01048 promotes cell proliferation and apoptosis in cutaneous squamous cell carcinoma by binding to TAF15 to transcriptionally activate YAP1. Cell Death Dis. 2019;10:296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6443651</ArticleId>
            <ArticleId IdType="pubmed">30931936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lv B, Zhang L, Miao R, et al. Comprehensive analysis and experimental verification of LINC01314 as a tumor suppressor in hepatoblastoma. Biomed Pharmacother. 2018;98:783‐792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29571247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lou C, Zhao J, Gu Y, et al. LINC01559 accelerates pancreatic cancer cell proliferation and migration through YAP‐mediated pathway. J Cell Physiol. 2020;235:3928‐3938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31608998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu Q, Li Y, Dong X, Yang Y, Wang H, Guo S. Linc‐OIP5 loss regulates migration and invasion in MDA‐MB‐231 breast cancer cells by inhibiting YAP1/JAG1 signaling. Oncol Lett. 2020;19:103‐112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6924107</ArticleId>
            <ArticleId IdType="pubmed">31897120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hu GW, Wu L, Kuang W, et al. Knockdown of linc‐OIP5 inhibits proliferation and migration of glioma cells through down‐regulation of YAP‐NOTCH signaling pathway. Gene. 2017;610:24‐31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28189759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu Q, Li J, Wu Q, et al. Linc‐OIP5 in the breast cancer cells regulates angiogenesis of human umbilical vein endothelial cells through YAP1/Notch/NRP1 signaling circuit at a tumor microenvironment. Biol Res. 2020;53:5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7014737</ArticleId>
            <ArticleId IdType="pubmed">32046779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang Y, Wang T, Wang S, et al. Nkx2‐2as suppression contributes to the pathogenesis of sonic hedgehog medulloblastoma. Cancer Res. 2018;78:962‐973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29229597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao W, Zhang LN, Wang XL, Zhang J, Yu HX. Long noncoding RNA NSCLCAT1 increases non‐small cell lung cancer cell invasion and migration through the Hippo signaling pathway by interacting with CDH1. FASEB J. 2019;33:1151‐1166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30148675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gao L, Cheng XL, Cao H. LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness. Biochimie. 2018;152:63‐72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29959065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu S, Yang Y, Wang W, Pan X. Long noncoding RNA TUG1 promotes cell proliferation and migration of renal cell carcinoma via regulation of YAP. J Cell Biochem. 2018;119:9694‐9706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30132963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li SY, Wang H, Mai HF, et al. Down‐regulated long non‐coding RNA RNAZFHX4‐AS1 suppresses invasion and migration of breast cancer cells via FAT4‐dependent Hippo signaling pathway. Cancer Gene Ther. 2019;26:374‐387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30546116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Qu L, Wu Z, Li Y, et al. A feed‐forward loop between lncARSR and YAP activity promotes expansion of renal tumour‐initiating cells. Nat Commun. 2016;7:12692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5133634</ArticleId>
            <ArticleId IdType="pubmed">27886176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Qin LT, Tang RX, Lin P, et al. Biological function of UCA1 in hepatocellular carcinoma and its clinical significance: Investigation with in vitro and meta‐analysis. Pathol Res Pract. 2018;214:1260‐1272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30017333</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
